453565-77-0

Upstream product

• 453565-76-9 methyl 3-cyano-5-hydroxy-benzoate 
• 627-42-9 2-chloroethyl methyl ether 
• 1149380-90-4 3-(methoxycarbonyl)-5-(2-methoxyethoxy)benzoic acid 
• 1149380-88-0 dimethyl 5-(2-methoxyethoxy)isophthalate 
• 13036-02-7 Dimethyl 5-hydroxyisophthalate 
• 1149380-92-6 methyl 3-carbamoyl-5-(2-methoxyethoxy)benzoate 

Downstream Products

• 1149380-86-8 (3-(imidazo[1,2-b]pyridazin-2-yl)-5-(2-methoxyethoxy)phenyl)methanamine 
• 1149380-96-0 3-(2-bromoacetyl)-5-(2-methoxyethoxy)benzonitrile 
• 1149380-98-2 3-(6-chloroimidazo[1,2-b]pyridazin-2-yl)-5-(2-methoxyethoxy)benzonitrile 
• 1149381-00-9 3-(imidazo[1,2-b]pyridazin-2-yl)-5-(2-methoxyethoxy)benzonitrile 
• 1149380-94-8 3-acetyl-5-(2-methoxyethoxy)benzonitrile 
• 453565-75-8 3-cyano-5-(2-methoxyethoxy)benzoic acid 

Relevant academic research and scientific papers

CYTOKINE INHIBITORS

Provided is a compound of Formula (I): and/or at least one pharmaceutically acceptable salt thereof. Also provided are a method of inhibiting the activity of at least one protein chosen from TNFα, IL-1β, NF-κB, IL-10 and iNOS, a method of decreasing a lev

CYTOKINE INHIBITORS

A compound of Formula I: Each variable is defined in the specification. This invention relates to a method of decreasing a level of a cytokine (e.g., TNFα or interlukine such as IL-1β) in a subject with a compound of Formula I. It also relates to a method

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.